Both the 2023 American College of Gastroenterology (ACG) Clinical Guideline on Alcohol-Associated Liver Disease and the 2019 American Association for the Study of Liver Diseases (AASLD) Practice Guidance discuss intravenous N-acetylcysteine (NAC) as an adjunct to corticosteroids in severe alcoholic hepatitis, but neither provides a specific dosing recommendation. Both guidelines note that the available evidence is based on studies using a 5-day intravenous NAC infusion administered with prednisolone and suggest that this combination may improve short-term (approximately 28- to 30-day or 1-month) survival; however, a sustained benefit at 3 or 6 months has not been demonstrated. The ACG guideline also notes that earlier studies of NAC monotherapy or NAC combined with other antioxidants did not demonstrate a survival benefit. Although individual randomized trials produced mixed findings, one 2015 network meta-analysis cited by both guidelines supported prednisolone plus 5 days of intravenous NAC as the regimen associated with the greatest short-term survival benefit, with the ACG guideline reporting an 85% reduction in the risk of death at 28 days and the AASLD guideline reporting a relative risk of 0.28 (95% credible interval 0.10 to 0.69). The ACG guideline states that IV NAC may be used as an adjunct to corticosteroids, citing its favorable safety profile, whereas the AASLD guidance considers the combination promising but notes that additional validation is needed. [1], [2], [3]
In a 2017 expert review published by the American Gastroenterological Association (AGA), alcoholic hepatitis is noted as an inflammatory disease, with cytokine production contributing to liver injury; thus, current drug therapies for severe alcoholic hepatitis have anti-inflammatory mechanisms of action. Glucocorticoids (e.g., methylprednisolone 32 mg daily) are considered the standard-of-care, though some patients are unable to tolerate or may have developed resistance to glucocorticoid therapy. In such cases, patients may be treated with pentoxifylline 400 mg three times daily with meals, though data to support this practice is still conflicting. Phosphodiesterase (PDE) inhibitors, particularly PDE-4 inhibitors, have been observed in vivo and in vitro to provide liver protection due to their ability to upregulate anti-inflammatory cytokines, though significant adverse events limit their role in treatment of alcoholic liver disease. Other treatments, such as vitamin E and NAC cocktails, have had limited or mixed success in other published literature; one combination of prednisolone and NAC, given intravenously over the first 5 days of treatment, resulted in significant improvement in 1-month mortality, which found mortality rate to be 16% lower than patients treated with prednisolone alone. Additionally, patients who were treated with prednisolone and NAC presented with fewer infections compared to those on prednisolone monotherapy (19% vs 42%; p= 0.001), as well as a lower incidence of hepatorenal syndrome (HRS; 12% vs 25%; p= 0.02). Though these findings are substantial, more research is required to confirm the benefits and most optimal use case of this regimen. [3], [4]
A 2026 systematic review and meta-analysis evaluated 52 randomized controlled trials involving 5,121 participants with severe alcohol-associated hepatitis to assess the efficacy and safety of pharmacologic therapies. Among the included studies, the addition of NAC to corticosteroids was associated with a significant reduction in 28-day mortality compared with corticosteroids alone (RR, 0.35; 95% CI, 0.16–0.78; 174 participants; 1 study), although no statistically significant benefit was observed for 90-day mortality (RR, 0.66; 95% CI, 0.41–1.08). Combination therapy was also associated with lower rates of infection (RR, 0.45; 95% CI, 0.27–0.75; moderate-certainty evidence) and progression to hepatorenal syndrome (RR, 0.48; 95% CI, 0.24–0.94; low-certainty evidence), with no significant difference in liver transplantation rates. The authors suggested that low-certainty evidence supports corticosteroids as first-line therapy for eligible patients with severe alcohol-associated hepatitis, while the evidence supporting adjunctive therapies, including NAC, ranges from low to moderate certainty and requires further confirmation. [5]